PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17878251-8	2007	Nude mouse xenograft tumors derived from the BRAF mutant line ARO exhibited dose-dependent growth inhibition by AZD6244, with effective treatment at 10 mg/kg by oral gavage.	AZD 6244	112-119	Braf transforming gene	Mus musculus	45-49	
24448821-7	2014	We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.	AZD 6244	122-133	Braf transforming gene	Mus musculus	50-54	
24132923-1	2013	PURPOSE: The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244).	AZD 6244	142-153	Braf transforming gene	Mus musculus	85-90	
24132923-13	2013	These results suggest dual targeting BRAF (V600E) signaling and STAT3 signaling may be effective in selumetinib-resistant tumors or may retard or prevent onset of resistance.	AZD 6244	100-111	Braf transforming gene	Mus musculus	37-41